News

Good news from a peer and a positive analyst update were the elements driving Viking Therapeutics (NASDAQ: VKTX) stock higher on the first trading day of the week.

The clinical-stage biotech

UnitedHealth Group (NYSE: UNH), by far the health insurance stock that's gotten most of the market's attention over the past few trading sessions, had a good Monday on the exchange. Its shares added

AbbVie (NYSE: ABBV) became a stand-alone, publicly traded company when it split from its former parent, Abbott Laboratories, in 2013. The reason for the split was for each company to generate

Pharmaceutical companies regularly encounter substantial headwinds. Among the most significant are patent cliffs -- when therapies lose patent exclusivity, inviting cheaper generic or biosimilar

Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares

Some smaller drugmakers choose to develop medicines for diseases for which there are no therapeutic options. This allows them to avoid direct competition from larger pharmaceutical companies.

That's

We're well into the home stretch of 2025. August is more than halfway over. But there's still plenty of time remaining in the year -- and in this month -- to invest in stocks that hold the potential

Dividend stocks are a great investment choice for many reasons. Buying on the dip is even better, provided, of course, they have the means to bounce back.

Investors looking for companies that fit

Despite President Donald Trump's trade wars and concerns about a possible recession, equity markets have performed relatively well this year, with the S&P 500 (SNPINDEX: ^GSPC) up 10% since January

In today's video, I discuss recent updates affecting Nvidia (NASDAQ: NVDA) and Advanced Micro Devices (NASDAQ: AMD). To learn more, check out the short video, consider subscribing, and click the

ImmuCell(NASDAQ:ICCC) reported results for the three-month period ended June 30, 2025, on August 14, 2025, highlighting a sharp rebound in profitability with adjusted EBITDA of $1.43 million

Even well-established drugmakers can lose significant market value overnight following a setback. That's what recently happened to Vertex Pharmaceuticals (NASDAQ: VRTX). The company's shares fell by

We've seen several investing trends sweep through Wall Street in recent years, from excitement about the cannabis market to the artificial intelligence (AI) industry that's now dominating headlines

In today's video, I discuss recent updates affecting Nvidia (NASDAQ: NVDA), Advanced Micro Devices (NASDAQ: AMD), and CoreWeave (NASDAQ: CRWV). To learn more, check out the short video, consider

Pfizer (NYSE: PFE) was a hot stock during the pandemic, but it has been crashing in recent years. The company's COVID vaccine resulted in the business posting record sales and profits in 2022. But

UnitedHealth Group (NYSE: UNH) has been a solid dividend growth stock for years. Generally, its yield has been fairly low, due to the stock's rising value. Even as the healthcare insurance giant has

TuHURA Biosciences (NASDAQ:HURA), a biotechnology company focused on immuno-oncology therapies, released its second quarter results on August 14, 2025. The big headlines included the start of a

ImmuCell (NASDAQ:ICCC), a specialist in animal health products for the dairy and beef industries, issued its earnings results for the second quarter of fiscal 2025 on August 14, 2025. The company

Tvardi Therapeutics (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on developing new therapies for serious diseases, released its second quarter fiscal 2025 results on August 14

Omeros (NASDAQ:OMER), a biopharmaceutical company focused on developing treatments for rare diseases and immune-related conditions, released its second quarter results on August 14, 2025. The

MacroGenics (NASDAQ:MGNX), a biotechnology company focused on antibody-based cancer treatments, reported its second-quarter results on August 14, 2025. The release showed GAAP revenue of $22.2

PAVmed (NASDAQ:PAVM), a medical technology innovator focused on minimally invasive diagnostics and digital health devices, published its earnings results on August 14, 2025. The headline news was a

Accuray reported fourth-quarter fiscal 2025 results on August 13, 2025, with $128 million in revenue (down 5% year-over-year), service revenue of $56.9 million (up 4% year-over-year), and adjusted

The market has abandoned UnitedHealth Group (NYSE: UNH), and that's exactly why I'm buying it. While investors flee the stock over rising medical costs and regulatory headlines, they're missing a

Medtronic (NYSE: MDT) isn't getting much love on Wall Street today. The stock has fallen around 33% since hitting a peak in mid-2021. That's a huge decline, but it may be overdone. Sure, there are